PuSH - Publikationsserver des Helmholtz Zentrums München

Mümmler, C. ; Dünzelmann, K. ; Kneidinger, N. ; Barnikel, M. ; Munker, D. ; Gröger, M.* ; Canis, M.* ; Behr, J. ; Koch, A.* ; Haubner, F.* ; Milger, K.*

Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP.

Clin. Transl. Allergy 11:e12049 (2021)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: We aimed to evaluate the effectiveness of different antibody therapies on nasal polyp symptoms in patients treated for severe asthma. METHODS: We performed a retrospective analysis of patients with severe asthma and comorbid CRSwNP who were treated with anti-IgE, anti-IL-5/R or anti-IL-4R. CRSwNP symptom burden was evaluated before and after 6 months of therapy. RESULTS: Fifty patients were included hereof treated with anti-IgE: 9, anti-IL-5/R: 26 and anti-IL-4R: 15 patients. At baseline median SNOT-20 was similar among groups (anti-IgE: 55, anti-IL-5/R: 52 and anti-IL-4R: 56, p = 0.76), median visual analogue scale (VAS) for nasal symptoms was 4, 7 and 8 (p = 0.14) and VAS for total symptoms was higher in the anti-IL-4R group (4, 5 and 8, p = 0.002). After 6 months SNOT-20 improved significantly in all patient groups with median improvement of anti-IgE: -8 (p < 0.01), anti-IL-5/R: -13 (p < 0.001) and anti-IL-4R: -18 (p < 0.001), with larger improvement in the anti-IL-4R group than in anti-IgE (p < 0.001) and anti-IL-5/R (p < 0.001) groups. VAS nasal symptoms improved by median anti-IgE: 0 (n.s.), anti-IL-5/R: -1 (p < 0.01) and anti-IL-4R: -3 (p < 0.001), VAS total symptoms by anti-IgE: -1 (n.s.), anti-IL-5/R: -2 (p < 0.001) and anti-IL-4R: -2 (p < 0.001). CONCLUSIONS: Treatment by all antibodies showed effectiveness in reducing symptoms of CRSwNP in patients with severe asthma, with the largest reduction observed in anti-IL-4R-treated patients.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Crswnp ; Antibody ; Asthma ; Benralizumab ; Biological ; Dupilumab ; Mepolizumab ; Nasal Polyps ; Omalizumab ; Real-life
e-ISSN 2045-7022
Quellenangaben Band: 11, Heft: 5, Seiten: , Artikelnummer: e12049 Supplement: ,
Verlag BioMed Central
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed